Adam Kruszewski

Joint Polish Investment Fund Management BV (Joint Polish Investment Fund Management) is a venture capital firm founded in 2015. The firm headquartered in Netherlands.

KCR SA provides clinical research services. It operates as a European contract research organization and strategic solutions provider for companies who are looking for a reliable alternative to global contract research organizations. The firm’s services include clinical trial, functional service provision, and late phase studies. It offers clinical project management, clinical monitoring, site management, feasibility studies, regulatory affairs, site start-up and contracting, biometrics and data management, quality assurance, cross-functional sourcing model, functional sourcing model, post-authorization efficacy study, post-authorization safety study, pricing and market access research, and case control study. The company was founded by Marek Kiecana in 1997 and is headquartered in Berlin, Germany.

GreenLeaf Medical AB provides natural ingredient food products. The private company is based in Stockholm, Sweden. The CEO of the Swedish company is Anders Struksnes.

Helix Immuno-Oncology SA engages in the research and development in the area of biotechnology. It develops technology and products with applications in cancer immunotherapy. The company was founded in 2013 and is headquartered in Gliwice, Poland.

Sound Object Technologies SA develops technology for obtaining and processing information from sound signals for application in medical devices. The company was founded by Adam Pluta and Piotr Smólski and in 2014 and is headquartered in Warsaw, Poland.

Chajec, Don-Siemion & Zyto Legal Advisors is a law firm based in Warsaw, Poland. The Polish company offers legal services in various areas such as capital markets, competition law, corporate and commercial law, employment law, insolvency and restructuring, intellectual property, litigation, mergers and acquisitions, personal data protection, project finance, public procurement, real estate and construction, tax law, and TMT. The firm has significant experience in leading and participating in integrated multi-disciplinary teams to provide seamless client advice. The company also has international expertise strengthened by working closely with Transatlantic Law International (TALI), a dynamic business law platform providing support on cross-border projects in 95 countries. The firm was founded by Andrzej Chajec and Ewa Don-Siemion.

Seal Rock Therapeutics, Inc. develops molecule inhibitors apoptosis, inflammation and fibrosis. The company was founded by Kathleen Elias, Neil McDonnell and Artur Plonowski is headquartered in Seattle, WA.

EMC Health Care Ltd. provides health care services. The private company is based in Dublin, Ireland.

Lab-Bit Software SA provides information technology software for the medical industry. It offers software solutions to hospitals, laboratories, and clinics. The company was founded in 1996 and is headquartered Bielany Wroclawskie, Poland.

Aescap Venture Management BV is an independent venture capital investment firm based in Amsterdam. Aescap was founded in 2005 by Michiel de Haan and Dinko Valerio. Inspired by the name of the Greek god of healthcare, Aesculapiu, the firm's name is an acronym for 'Accelerating European Science Companies and Products.' The firm focuses on developing growth in European firms in the biomedical sector.

F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria.

Vasa Therapeutics, Inc. is a private biotechnology company based in Encinitas, CA, committed to discovering and developing transformative therapies for vascular diseases such as heart failure, peripheral artery disease, and sarcopenia. The company's cutting-edge computational chemistry and design platform integrates everything from the identification of viable biological targets to the design and identification of small molecule or peptide therapeutics. Vasa has three active preclinical programs, two small molecule programs focused on the treatment of cardiovascular disease and one peptide therapeutic program aimed at identifying a novel treatment for peripheral artery disease and sarcopenia. The company has a world-class, founder-led team with an outstanding track record of successful development of numerous clinical candidates and commercial drugs spanning multiple therapeutic areas and modalities resulting in several exits values at greater than $1b (USD). The CEO of the company is Mark Robert Herbert.